Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:
AcuityAds ATY is a technology company which provides marketers a one-stop solution for omnichannel digital advertising. The Zacks Consensus Estimate for its current year earnings has been revised 62.5% downward over the last 60 days.
ATI Physical Therapy ATIP is a portfolio company of Advent International as well as provider of outpatient physical therapy services. The Zacks Consensus Estimate for its current year earnings has been revised 28.6% downward over the last 60 days.
APA APA is one of the world’s leading independent energy companies engaged in the exploration, development and production of natural gas, crude oil and natural gas liquids. The Zacks Consensus Estimate for its current year earnings has been revised almost 9.3% downward over the last 60 days.
View the entire Zacks Rank #5 List.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
APA Corporation (APA) : Free Stock Analysis Report
AcuityAds Holdings Inc. (ATY) : Free Stock Analysis Report
ATI Physical Therapy, Inc. (ATIP) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.